Market Research Logo

Global Central Nervous System (CNS) Biomarkers by Country (United States, Canada, India, China, Japan, United Kingdom), Company Profiles, Share, Trends, Analysis, Opportunities, Segmentation and Forecast 2015 – 2021

Global Central Nervous System (CNS) Biomarkers by Country (United States, Canada, India, China, Japan, United Kingdom), Company Profiles, Share, Trends, Analysis, Opportunities, Segmentation and Forecast 2015 – 2021

Global CNS biomarker market development in proteomics, genomics and imaging system has increased demand for CNS biomarker says a new report by Occams Research.

Global gene expression profiling by genomic and proteomic analyses has changed the face of drug discovery and biological research in the past few years. The benefit of these technologies in the area of process development for recombinant protein production has been increasingly realized. This review discusses the application of genome-wide expression profiling tools in the design and optimization of bioprocesses with the emphasis on the effect on process development of mammalian cell culture.

However, “High cost of CNS biomarker test and diagnostics” are considered to be hindrance in the growth of CNS biomarker market. Reimbursement issues are affecting the CNS biomarker market, the diagnosis through CNS biomarker are costly and may not be reimbursed which is a concern for the CNS biomarker market.

“Increasing adoption of personalized medicines is considered to be fruitful for CNS market expansion. Exploration of untapped APAC region has created huge scope for CNS biomarker market and in the next few years the market is looking lucrative.

“Creating awareness for CNS biomarker market is major challenge” which is still a concern in the emerging economies such as China, India and Japan.

Companies Profiled

1. Abastar MDX Inc
2. Thermo fisher scientific
3. Abiant Inc
4. EKFdiagnostics holdings inc
5. Enzo biochem inc
6. Acumen pharmaceuticals Inc
7. Adlyfe Inc
8. Alseres pharmaceuticals Inc
9. Apitope international
10. Aposense
11. Applied neurosolutions Inc
12. Avacta group plc
13. Merck & co inc
14. Avid radiopharmaceuticals Inc
15. Banyan biomarkers
16. Diagenic ASA
17. Exonhit therapeutics
18. Genenews ltd
19. Glycominds ltd
20. Great lakes neurotechnologies
21. Innogenetics biologicals
22. Innovative neurotechnologies inc
23. Metabolon inc
24. Myriad RBM inc
25. Oligomerix inc
26. Opko health inc
27. Osta biotechnologies inc
28. Proteome sciences products
29. Psynova neurotech ltd
30. Ridge diagnostics
31. Satori pharmaceutical inc
32. Sabiosciences

This Occams Research Report covers

1. Historical data
2. Revenue forecasts, growth rates and CAGR upto 2021
3. Industry Analysis
4. Competitive Analysis
5. Key geographic growth data
6. In-depth profiling of companies

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.


1. Introduction
1.1. Executive summary
1.2. Estimation methodology
2. Market overview
2.1. Market definition and scope
2.2. Key findings
2.3. Parametric analysis
2.3.1. Prevalence & incidence rate of alzheimer’s disease
2.3.2. Hospital and research center across geographies
2.3.3. Prevalence & incidence rate of parkinson’s disease
2.3.4. Prevalence & incidence rate of cancer disease
2.3.5. Healthcare expenditure across geographies
2.4. Key market insights
2.4.1. Top 3 emerging countries
2.4.2. Top 3 revenue generating segments
2.4.3. Top growing markets and emerging trends
2.4.4. Pipeline analysis
2.4.5. Patent analysis
2.4.5.1. Patents for alzheimer’s disease biomarkers
2.4.5.2. Patents for multiple sclerosis biomarkers
2.4.5.3. Patents for parkinson’s disease biomarkers
2.4.5.4. Patents for ALS disease biomarkers
2.4.6. R&D scenario in CNS biomarker market
2.4.6.1. R&d in genomics
2.4.6.2. R&d in proteomics
2.4.6.3. Clinical trials on drug biomarkers in major CNS diseases
2.4.6.4. Clinical trials on diagnostic test biomarkers in major CNS diseases
2.5. Competitive intelligence
2.5.1. Market share analysis
2.5.2. Top winning strategies
2.5.3. Case studies: top competitive moves
2.6. Value chain analysis
2.7. Key buying criteria
2.8. Strategic recommendation
2.9. Strategic conclusions
3. Market determinants
3.1. Market drivers
3.1.1. Development in proteomics, genomics and imaging system has increased demand for CNS biomarker.
3.1.2. Funding from government and private players to boost CNS biomarker market
3.1.3. Growth in life style oriented diseases
3.1.4. Growth in government and private funding in CNS biomarker market
3.1.5. Growth in public-private partnership
3.1.6. FDA approvals giving rise to significant scope in biomarker market
3.1.7. Technological advancement enables to expand CNS biomarker market
3.1.8. Innovation giving rise to growth of CNS biomarker market
3.1.9. Global increase in healthcare expenditure
3.2. Market restraints
3.2.1. High cost of CNS biomarker test and diagnostics
3.2.2. Reimbursement issues affecting the CNS biomarker market
3.3. Market challenges
3.3.1. Creating awareness for CNS biomarker market
3.3.2. Global economic slowdown may affect the CNS biomarker market
3.3.3. Technical issues of sample collection and storage
3.4. Market opportunities
3.4.1. Increasing adoption of personalized medicines
3.4.2. Untapped APAC region has huge scope for CNS biomarker market
3.4.3. Global increase in aging population has created huge scope for CNS biomarker market
3.4.4. Favorable government policies and support for CNS biomarkers
4. Sector Analysis
4.1. Parent market
4.2. Sub-segment market
4.3. Alternative market
5. Market Segmentation
5.1. Global CNS biomarker market
5.1.1. Global CNS biomarker market by application, 2014-2021,($ millions)
5.1.1.1. Global diagnostic development market, 2014-2021,($ millions)
5.1.1.2. Global drug discovery and development market, 2014-2021,($ millions)
5.1.1.3. Global personalized medicine market, 2014-2021,($ millions)
5.1.1.4. Global disease risk assessment market, 2014-2021,($ millions)
5.1.1.5. Global other market , 2014-2021,($ millions)
5.1.2. Global CNS biomarker market by type, 2014-2021,($ millions)
5.1.2.1. Global safety biomarker market , 2014-2021,($ millions)
5.1.2.2. Global efficacy biomarker market, 2014-2021,($ millions)
5.1.2.2.1. Global predictive biomarker market, 2014-2021,($ millions)
5.1.2.2.1.1. , 2014-2021,($ millions)
5.1.2.2.2. Global pharmacodynamic biomarker market, 2014-2021,($ millions)
5.1.2.2.3. Global prognostic biomarker market, 2014-2021,($ millions)
5.1.2.3. Global validation biomarker market, 2014-2021,($ millions)
5.2. Global CNS biomarker by end user, 2014-2021,($ millions)
5.2.1. Hospitals
5.2.2. Eye clinics
5.2.3. Diagnostic centers
5.2.4. Patients
6. Competitive Landscape
6.1. Market share
6.2. Strategy – An analysis across tiers
7. Geographical analysis
7.1. North America CNS biomarker market, 2014-2021,($millions)
7.1.1. United States (U.S.) CNS biomarker market, 2014-2021,($millions)
7.1.2. Canada CNS biomarker market, 2014-2021,($millions)
7.2. Europe CNS biomarker market, 2014-2021,($millions)
7.2.1. United Kingdom CNS biomarker (UK) market, 2014-2021,($millions)
7.2.2. France CNS biomarker market, 2014-2021,($millions)
7.2.3. Germany CNS biomarker market, 2014-2021,($millions)
7.2.4. Spain CNS biomarker market, 2014-2021,($millions)
7.2.5. Italy CNS biomarker market, 2014-2021,($millions)
7.2.6. RoE CNS biomarker market, 2014-2021,($millions)
7.3. Asia Pacific CNS biomarker market, 2014-2021,($millions)
7.3.1. India CNS biomarker market, 2014-2021,($millions)
7.3.2. China CNS biomarker market, 2014-2021,($millions)
7.3.3. Japan CNS biomarker market, 2014-2021,($millions)
7.3.4. Korea CNS biomarker market, 2014-2021,($millions)
7.3.5. Australia CNS biomarker market, 2014-2021,($millions)
7.3.6. RoAPAC CNS biomarker market, 2014-2021,($millions)
7.4. Rest of the world market, 2014-2021,($millions)
7.4.1. Latin America CNS biomarker market, 2014-2021,($millions)
7.4.2. MENA CNS biomarker market, 2014-2021,($millions)
7.4.3. Africa CNS biomarker market, 2014-2021,($millions)
8. Company Profiling: - (Over, SCOT analysis, strategic review)
8.1. Abastar MDX Inc
8.2. Thermo fisher scientific
8.3. Abiant Inc
8.4. EKFdiagnostics holdings inc
8.5. Enzo biochem inc
8.6. Acumen pharmaceuticals Inc
8.7. Adlyfe Inc
8.8. Alseres pharmaceuticals Inc
8.9. Apitope international
8.10. Aposense
8.11. Applied neurosolutions Inc
8.12. Avacta group plc
8.13. Merc & co. in
8.14. Avid radiopharmaceuticals Inc
8.15. Banyan biomarkers
8.16. Diagenic ASA
8.17. Exonhit therapeutics
8.18. Genenews ltd
8.19. Glycominds ltd
8.20. Great lakes neurotechnologies
8.21. Innogenetics biologicals
8.22. Innovative neurotechnologies inc
8.23. Metabolon inc
8.24. Myriad RBM inc
8.25. Oligomerix inc
8.26. Opko health inc
8.27. Osta biotechnologies inc
8.28. Proteome sciences products
8.29. Psynova neurotech ltd
8.30. Ridge diagnostics
8.31. Satori pharmaceutical inc
8.32. Sabiosciences
List of tables
1. Global CNS biomarker market by application, 2014-2021,($ millions)
2. Global diagnostic development market, 2014-2021,($ millions)
3. Global drug discovery and development market, 2014-2021,($ millions)
4. Global personalized medicine market, 2014-2021,($ millions)
5. Global disease risk assessment market, 2014-2021,($ millions)
6. Global other market , 2014-2021,($ millions)
7. Global CNS biomarker market by type, 2014-2021,($ millions)
8. Global safety biomarker market , 2014-2021,($ millions)
9. Global efficacy biomarker market, 2014-2021,($ millions)
10. Global predictive biomarker market, 2014-2021,($ millions)
11. Global surrogate biomarker market, 2014-2021,($ millions)
12. Global pharmacodynamic biomarker market, 2014-2021,($ millions)
13. Global prognostic biomarker market, 2014-2021,($ millions)
14. Global validation biomarker market, 2014-2021,($ millions)
15. Global CNS biomarker by end user, 2014-2021,($ millions)
16. Global Hospitals market, 2014-2021,($ millions)
17. Global Eye clinics market, 2014-2021,($ millions)
18. Global Diagnostic centers market, 2014-2021,($ millions)
19. Global Patients market, 2014-2021,($ millions)
List of figures
1. United States (U.S.) CNS biomarker market, 2014-2021,($millions)
2. Canada CNS biomarker market, 2014-2021,($millions)
3. India CNS biomarker market, 2014-2021,($millions)
4. China CNS biomarker market, 2014-2021,($millions)
5. Japan CNS biomarker market, 2014-2021,($millions)
6. Korea CNS biomarker market, 2014-2021,($millions)
7. Australia CNS biomarker market, 2014-2021,($millions)
8. RoAPAC CNS biomarker market, 2014-2021,($millions)
9. Latin America CNS biomarker market, 2014-2021,($millions)
10. MENA CNS biomarker market, 2014-2021,($millions)
11. Africa CNS biomarker market, 2014-2021,($millions)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report